Presenter Disclosure Information

Slides:

Advertisements

Similar presentations

Prevalence and Predictors of Off-label Use of Cardiac Resynchronization Therapy: A Report from the ICD Registry TM Adam S. Fein * MD, Yongfei Wang ¥ MS,

Advertisements

The MADIT II Trial Multicenter Autonomic Defibrillator Implantation Trial II Presented at the American College of Cardiology 51st Annual Scientific Session.

The ABC’s of the AHA/ACC Prevention Guidelines

Sudden Cardiac Death Prevention: Clinical Trials Alena Goldman, MD September 9, 2004.

Is Participation in Get With the Guidelines-Resuscitation Program Associated with Improved Quality of Cardiac Arrest Care? Monique L. Anderson, MD, Graham.

MADIT Randomized Trial to Reduce Inappropriate Therapy (MADIT-RIT) Arthur J. Moss, MD for the MADIT-RIT Executive Committee AHA Late Breaking Trials November.

Impact of Anticoagulant and Anti-platelet Therapy on ICD Implant-Related Bleeding and Thromboembolic Events in Patients Enrolled in the NCDR ® ICD Registry.

La stratificazione del rischio aritmico oltre la frazione di eiezione Milano 17 Aprile 2009 Prof. Luigi Padeletti Heart Failure & Co.

Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.

Prevention de la Mort Subite Treatment of Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death S. Nasr, M.D. Clinical Cardiac Electrophysiologist.

Hypertrophic Cardiomyopathy Guidelines Summary from the: ACC/ESC Clinical Expert Consensus Statement on Hypertrophic Cardiomyopathy Maron BJ, et al. J.

Implantable Cardioverter Defibrillators to Prevent Sudden Cardiac Death: Background Frederick A. Masoudi, MD, MSPH Associate Professor of Medicine (Cardiology)

Implementation of ESC/ACC Definition of Myocardial Infarction in Contemporary, Large RCTs: A Systematic Review Sergio Leonardi, L. Kristin Newby, E. Magnus.

Optimization of CRT via EKG Is simple better? Winter Arrhythmia School February 11, 2012 Irving Tiong, MD FRCPC Arrhythmia Service.

CRT-D Effectiveness by QRS Duration and Morphology in the MADIT-CRT Patients Wojciech Zareba, MD, PhD, Helmut Klein, MD, Iwona Cygankiewicz, MD, PhD, W.

Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,

Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker,

Heartland Cardiology Dr. John Dongas The Beat Goes On: Biventricular Devices.

The Current Indications for ICD in HF Patients Should be Driven by HF Guidelines Mariell Jessup MD Professor of Medicine University of Pennsylvania Philadelphia,

Alon Barsheshet, MD1, Paul J. Wang, MD2, Arthur J. Moss, MD1, Scott D

Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.

EP Show – Aug 2003 ICDs – Primary prevention The EP Show: Which ICD for which patient? Part 2: Primary prevention Eric Prystowsky MD Director, Clinical.

LONG-TERM SURVIVAL WITH CARDIAC RESYNCHRONIZATION THERAPY IN MILD HEART FAILURE PATIENTS Ilan Goldenberg, MD, Valentina Kutyifa, MD, PhD, Helmut Klein,

Renal function and clinical outcomes of patients undergoing ICD and CRTD implantation- Data from the Israeli ICD Registry Alon Eisen, Mahmoud Souleiman,

Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.

EP Show – April 2002 MADIT II The EP Show: MADIT II Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital The Care Group.

Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, General Medicine,

Risk of Life-Threatening Cardiac Events in Patients with Genotype-Confirmed Long-QT Syndrome and a Normal-Range QTc Ilan Goldenberg, MD,* Samuel Horr,

EP Show – Aug 2003 ICDs – Secondary prevention The EP Show: Which ICD for which patient? Part 1: Secondary prevention Eric Prystowsky MD Director, Clinical.

ICD Indications T he Guidelines and Beyond University of Minnesota Medical Center Fei Lü, M.D., Ph.D., F.A.C.C., F.H.R.S. Associate Professor of Medicine.

EP show – June 2004 EP show The EP show: Risk stratification for sudden death Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent.

An ICD for every CRT patient ?

EP Show – Dec 2003 ICDs – Primary prevention The EP Show: Guidelines and reimbursement at the crossroads: Primary prevention with ICDs Eric Prystowsky.

Use of lung function tests in paediatric asthma care A nationwide registry study Grete Moth, MHSc, Ph.D Danish Paediatric Asthma Centre Aarhus University.

Increased Patient Device Concerns But Not General Anxiety in Patients with a Secondary Indication for the ICD Susanne S. Pedersen, Professor of Cardiac.

CoRPS Center of Research on Psychology in Somatic diseases Poor health status in implantable cardioverter defibrillator patients: Shock, patient pre implantation.

CoRPS Center of Research on Psychology in Somatic diseases Depression is associated with a 2-fold independent risk of mortality in implantable cardioverter.

Author Disclosure Sex Differences in the Characteristics of Patients Receiving ICD Therapy for the Primary Prevention of Sudden Cardiac Death –Stacie L.

Comparison of Low Versus High (>40 mm Hg) Pulse Pressure to Predict the Benefit of Cardiac Resynchronization Therapy for Heart Failure (from the Multicenter.

American Heart Journal

Revascularization in Patients With Left Ventricular Dysfunction:

Surviving as a Survivor

2) Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114

Risk of Recurrent Cardiac Events After Onset of Menopause in Women With Congenital Long-QT Syndrome Types 1 and 2Clinical Perspective by Jonathan Buber,

Preventing SCD With a WCD: Reviewing the Results of the VEST Trial

Addressing Patients at High Risk for SCA

Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection Derek V. Exner, MD, MPH, David.

Hepatitis C in the HIV-infected patient

Remote Patient Management:

Volume 9, Issue 8, Pages S3-S13 (August 2012)

Long-Term survival with Cardiac Resynchronization Therapy in Mild Heart Failure patients Ilan Goldenberg, MD, Valentina Kutyifa, MD, PhD, Helmut Klein,

Andre J. Gauri, MD, Andrew Davis, MD, Thomas Hong, MD, Martin C

Belinda Gray et al. JCHF 2013;1:

The EP Show: CMS reimbursement decision for ICDs

David F. Katz et al. JACEP 2016;j.jacep

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

Volume 15, Issue 10, Pages e253-e274 (October 2018)

3 to 4 million patients fit the entry criteria

Prabhat Kumar et al. JACEP 2016;j.jacep

Angelo Auricchio, and Frits W. Prinzen JACEP 2017;j.jacep

International primary care snapshots: Israel and China

Volume 9, Issue 1, Pages (January 2012)

David F. Katz et al. JACEP 2017;3:20-28

Maria R. Costanzo et al. JCHF 2016;4:

Volume 6, Issue 2, Pages (February 2009)

Jordan S. Leyton-Mange et al. JACEP 2017;j.jacep

Figure 1 Distribution of WCD use days in WEARIT-II

Saadia Sherazi et al. JACEP 2015;1:74-80

THE TITLE OF MY TALK John Doe, M.D. Professor Department of Neurology

Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.

Presentation transcript:

Presenter Disclosure Information Valentina Kutyifa, MD, PhD Results From The Prospective Registry Of Patients Using The Wearable Defibrillator (WEARIT-II Registry) DISCLOSURE INFORMATION The following relationships exist related to this presentation: WEARIT-II was supported by ZOLL.

Results From The Prospective Registry Of Patients Using The Wearable Defibrillator (WEARIT-II Registry) Valentina, Kutyifa, MD, PhD, Ilan Goldenberg, MD, Wojciech Zareba, MD, PhD, Helmut Klein, MD, Chingping Wan, MD, Bonnie MacKecknie, Mark L. Andrews, MS, Steve Szymkiewicz, MD and Arthur J. Moss, MD From the Cardiology Division of the Department of Medicine (VK, IG, WZ, HK, BM, MLA, AJM), University of Rochester Medical Center, Rochester, N.Y.; Sheba Medical Center and Tel Aviv University, Israel (IG); and ZOLL, Pittsburgh, PA (SS, CW)

Background: Current Guidelines for Primary ICD Therapy EF ≤ 35% High-risk inherited arrhythmias AHA/ACC/HRS 2012 Guidelines 0.64

BACKGROUND: NEED FOR IMPROVED SELECTION OF PATIENTS FOR PRIMARY ICD THERAPY MADIT-II: Only one third of pts received appropriate ICD therapy over 4 years of FU Moss et al. NEJM 2002 MADIT-RIT: ICD programing to <200 bpm is associated with increased risk for inappropriate Rx and mortality Rate of appropriate ICD shocks was only 4% (event rate: 3 appr. ICD shocks per 100 pt-yrs) Moss et al. NEJM 2012

LIFEVEST WEARABLE CARDIOVERTER DEFIBRILLATOR (WCD) Can be used to bridge a decision for appropriate ICD therapy in: Post-MI pts Following coronary revascularization New onset dilated (non-ischemic) CMP High risk patients until stabilization Inherited arrhythmic or congenital disorders Availability of response button can be used to reduce inappropriate Rx

Study Purpose To provide prospective data on the safety and efficacy of a bridging strategy with the WCD in a real world setting

WEARIT-II: REGISTRY DESIGN WCD (LifeVest) prescription in the US Informed consent Acquisition of baseline clinical data Wearing time: 3 months Clinical and Arrhythmic event acquisition WCD return: end of use evaluation 12 month FU

STUDY POPULATION N= 2000 patients enrolled in the US Currently enrolling patients in Europe, Israel Study duration: August 2011 – December 2013 Data management: University of Rochester Ischemic cardiomyopathy 805 pts, 40.3% Non-ischemic CMP 927 pts, 46.4% Cong/inherited 268 pts, 13.4%

CONGENITAL, INHERITED HEART DISEASE Initial diagnosis at baseline (n=268, 13.4%) * Allows for multiple diagnoses.

CHARACTERISTICS OF PATIENTS All Patients N=2000 Ischemic N=805 Non-ischemic N=927 Cong/Inherited N=268 Age, yrs (median) 62 65 59† 59* Female 30% 23% 36%† 30%* EF (median) 25% 25% † 25% * HF symptoms 52% 48% 63%* Diabetes 28% 35% 21%† Prior ACA 9% 11% 7%† 7% * p-value < 0.05 ischemic, non-ischemic, cong/inherited, † p-value < 0.05 ischemic, non-ischemic Data are reported by patients using a baseline evaluation form.

ARRHYTHMIC EVENTS: TOTAL POPULATION (WEAR DAYS MEDIAN 90 days) Patients (%) Events (events/pt) Event Rate Per 100 Pt-Year Any VT/VF * 41 (2.1%) 120 (2.9) 22 NSVT 28 (1.4%) 164 (5.9) 30 Atrial arrhythmias/SVT 72 (3.6%) 561 (7.8) 121 Asystole 6 (0.3%) 9 (1.5) 2 *Treated VT/VF and those VT’s that were spontaneously terminated, response button use or extended detection time.

ARRHYTHMIC EVENTS: WEARIT-II VS. MADIT-RIT MADIT-RIT Arms B&C

ANY VT/VF BY DISEASE ETIOLOGY

SAFETY END POINTS TYPE TOTAL N=2000 Inappropriate Rx, n (%) 10 (0.5%) Death, n (%) with the WCD 3 (0.2%)* * WCD detected asystole at the time of death No death related to unsuccessful termination of VT/VF 12-m FU data on death are still being collected

COMPLIANCE Daily wear hours: median 22.5 hours

COMPLIANCE BY DISEASE ETIOLOGY

END OF USE BY ETIOLOGY

DETECTED WCD ARRHYTHMIAS AND END OF USE DECISION

CONCLUSIONS In a real world setting a management strategy that incorporates the WCD can be safely used to bridge a decision for appropriate ICD therapy in patients with acquired, inherited, and congenital, heart disease: Safe termination of life-threatening arrhythmic events Low rate of inappropriate therapies Risk assessment tool to identify patients at higher risk for SCD who need subsequent ICD implantation

Thank You